Skye Bioscience, Inc.
SKYE Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$1.45
KIRA · Stoqly’s AI analyst, in plain words
- Skye Bioscience, Inc. lost $55.9M in fiscal 2025.
- Free cash flow was −$43.1M in fiscal 2025, — of revenue.
Market cap
$57.6M
P/E
—
Revenue
—
Net income
−$55.9M
Free cash flow
−$43.1M
Operating margin
—
Skye Bioscience, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$55.9M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Skye Bioscience, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- Skye Bioscience, Inc.
- CIK
- 0001516551
Skye Bioscience, Inc. · SKYE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$8.5M | −$19.5M | −$37.6M | −$26.6M | −$55.9M |
| Diluted EPS | −$0.02 | −$8.77 | −$5.37 | −$0.73 | −$1.41 |
| Cash | |||||
| Cash from operations | −$6.5M | −$12.7M | −$14.0M | −$25.2M | −$43.1M |
| Capital expenditure | $0.1M | $0.0M | $0.0M | $1.6M | $0.0M |
| Free cash flow | −$6.6M | −$12.8M | −$14.0M | −$26.8M | −$43.1M |
| Share count change | 75.7% | −99.5% | 215.4% | 420.8% | 8.7% |
| Debt and strength | |||||
| Cash and short-term investments | $9.0M | $1.2M | $1.3M | $68.4M | $25.7M |
| Shareholders' equity | $5.9M | −$3.0M | −$2.1M | $68.2M | $20.0M |
| Current ratio | 2.5x | 0.7x | 0.8x | 16.3x | 3.3x |
| Interest coverage | −10.2x | −27.5x | −38.3x | −40.3x | — |
| Returns and quality | |||||
| Return on equity | −269.9% | −1,364.2% | — | −80.5% | −126.8% |
| Return on tangible equity | −145.3% | — | — | −39.0% | −279.3% |
| Altman Z'' | −15.6 | −39.9 | −49.4 | 12.9 | −28.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.9M
4 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Skye Bioscience, Inc. · SKYE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.45 a share, the company is worth $57.6M.
Source: SEC EDGAR XBRL filings (CIK 0001516551). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.